Abbott starts new trial to assess early use benefit of HeartMate 3

Abbott has launched a “first-of-its-kind” trial to identify advanced heart failure patients who could potentially benefit from early advanced therapy options, namely HeartMate 3 left ventricular assist device (LVAD).